Filing Details

Accession Number:
0001714899-24-000092
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-19 16:27:41
Reporting Period:
2024-03-15
Accepted Time:
2024-03-19 16:27:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1197020 L Vicki Sato C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-03-15 1,666 $20.10 119,709 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.
  2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.72 to $20.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. Includes 4,216 unvested RSUs.